Oric: Collaboration with Pfizer for ORIC-533 in Multiple Myeloma, Concurrent $25 M Equity Investment

 ORIC and Pfizer have entered into a clinical development collaboration for a Phase 2 study of ORIC-533 in combination with elranatamab in multiple myeloma

Jeff Settleman, Ph.D., Chief Scientific Officer, Pfizer Oncology, to join ORIC Scientific Advisory Board

Including $25 million equity investment from Pfizer, ORIC cash runway extended into 1H 2025

https://finance.yahoo.com/news/oric-pharmaceuticals-announces-clinical-development-224800151.html